Target Name: MRPS6
NCBI ID: G64968
Review Report on MRPS6 Target / Biomarker Content of Review Report on MRPS6 Target / Biomarker
MRPS6
Other Name(s): RT06_HUMAN | S6mt | 28S ribosomal protein S6, mitochondrial | Mitochondrial small ribosomal subunit protein bS6m | mitochondrial ribosomal protein S6 | MRP-S6 | Mitochondrial ribosomal protein S6 | mitochondrial small ribosomal subunit protein bS6m | C21orf101 | RPMS6

MRPS6: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

MRPS6 (microRNA-protein 6) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in disease progression and treatment.

MRPS6 is a small RNA molecule that contains 20-22 amino acid residues. It is primarily expressed in the brain and is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. It is also known to play a role in modulating inflammation and has been linked to various neurological disorders.

One of the unique features of MRPS6 is its ability to interact with other molecules and adapter proteins. This interaction allows MRPS6 to regulate the activity of various proteins and create a complex network of regulation in the cell. One of the well-known proteins that it interacts with is the protein runner(RUNX1), which is involved in cell growth, differentiation, and survival.

Research has shown that MRPS6 can inhibit the activity of RUNX1 and reduce its levels in the brain. This suggests that MRPS6 may be a potential drug target for diseases that are characterized by the over-expression of RUNX1. One of the potential benefits of targeting RUNX1 with MRPS6 is that it could be a highly effective therapy for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Another potential drug target for MRPS6 is the protein IDH1, which is involved in cell growth, proliferation, and repair. Studies have shown that MRPS6 can interact with IDH1 and reduce its activity in the brain. This suggests that MRPS6 may be a potential target for diseases that are characterized by the over-expression of IDH1. One of the potential benefits of targeting IDH1 with MRPS6 is that it could be a highly effective therapy for neurodegenerative diseases, as well as a potential cancer therapeutic.

In addition to its potential drug targets, MRPS6 has also been shown to be a potential biomarker for various diseases. Studies have shown that MRPS6 levels can be affected by various factors, including aging, stress, and disease. This suggests that MRPS6 may be a potential indicator of disease severity and response to therapy. In addition, MRPS6 levels have also been shown to be affected by certain medications, such as chemotherapy and radiation therapy. This suggests that MRPS6 may be a potential biomarker for these types of treatments.

Overall, MRPS6 is a fascinating molecule that has the potential to be a drug target and biomarker for various diseases. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in disease progression and treatment. Further research is needed to fully understand the role of MRPS6 in disease and to develop effective therapies based on its unique properties.

Protein Name: Mitochondrial Ribosomal Protein S6

The "MRPS6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPS6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MRPS7 | MRPS9 | MRRF | MRS2 | MRS2P2 | MRTFA | MRTFB | MRTO4 | MS4A1 | MS4A10 | MS4A12 | MS4A13 | MS4A14 | MS4A15 | MS4A18 | MS4A2 | MS4A3 | MS4A4A | MS4A4E | MS4A5 | MS4A6A | MS4A6E | MS4A7 | MS4A8 | MSANTD1 | MSANTD2 | MSANTD3 | MSANTD4 | MSC | MSC-AS1 | MSGN1 | MSH2 | MSH3 | MSH4 | MSH5 | MSH5-SAPCD1 | MSH6 | MSI1 | MSI2 | MSL1 | MSL2 | MSL3 | MSL3P1 | MSLN | MSLNL | MSMB | MSMO1 | MSMP | MSN | MSNP1 | MSR1 | MSRA | MSRA-DT | MSRB1 | MSRB1P1 | MSRB2 | MSRB3 | MSRB3-AS1 | MSS51 | MST1 | MST1L | MST1P2 | MST1R | MSTN | MSTO1 | MSTO2P | MSX1 | MSX2 | MSX2P1 | MT1A | MT1B | MT1DP | MT1E | MT1F | MT1G | MT1H | MT1HL1 | MT1IP | MT1JP | MT1L | MT1M | MT1P1 | MT1P3 | MT1X | MT1XP1 | MT2A | MT3 | MT4 | MTA1 | MTA1-DT | MTA2 | MTA3 | MTAP | MTARC1 | MTARC2 | MTATP6P1 | MTATP8P1 | MTBP | MTCH1 | MTCH2